Impact of intravesical chemotherapy versus BCG immunotherapy on recurrence of superficial transitional cell carcinoma of the bladder: Metaanalytic reevaluation

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 26, Issue 4, 2003, Pages 402-407

  Huncharek, Michael ^a,b   Kupelnick, Bruce ^b  

^a MARSHFIELD CLINIC   (United States)

^b Meta Analysis Research Group   (United States)

Author keywords

Bladder cancer; Chemotherapy; Immunotherapy; Metaanalysis

Indexed keywords

BCG VACCINE; DOXORUBICIN; EPIRUBICIN; MITOMYCIN C; THIOTEPA;

ARTICLE; BCG VACCINATION; BLADDER CARCINOMA; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG EFFICACY; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MEDICAL LITERATURE; META ANALYSIS; OUTCOMES RESEARCH; PROSPECTIVE STUDY; PUBLICATION; RANDOMIZED CONTROLLED TRIAL; SUPERFICIAL CANCER; TRANSITIONAL CELL CARCINOMA; TREATMENT FAILURE;

EID: 0041561276     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.COC.0000026911.98171.C6     Document Type: Article

References (29)

1. Wingo PA, Tong T, Bolden S. Cancer statistics. CA 1995;45:8.
2. Abdel PD. Follow-up of patients with superficial transitional cell carcinoma of the bladder. Case for change in policy. Br J Urol 1993;72:125-30.
3. Lamm DL, Riggs DR, Traynelis C, et al. Apparent failure of current intravesical chemotherapy prophylaxis to influence the long term course of superficial transitional cell carcinoma of the bladder. J Urol 1995;153:1444-50.
4. Cooper H, Hedges LV. The handbook of research synthesis. New York: Russell Sage Foundation, 1994.
5. Yusuf S, Peto R, Lewis J, et al. Beta-blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis 1985;7:335-71.
6. Petitti DB. Meta-analysis, decision analysis and cost-effectiveness analysis. Methods for quantitative synthesis in medicine. 2nd ed. New York: Oxford University Press, 2000.
7. Brosman SA. Experience with Bacillus Calmette-Guerin in patients with superficial bladder carcinoma. J Urol 1982;128:27-30.
8. Debruyne FMJ, Meijden APM, Geboers AH, et al. BCG (RIVM) versus mitomycin C intravesical therapy in superficial bladder cancer. Urology (Suppl) 1988;30:20-5.
9. Debruyne FMJ, van der Meijden APM, Franssen MPH. BCG (RIVM) versus mitomycin intravesical therapy in patients with superficial bladder cancer. In: Therapeutic progress in urological cancers. New York: Alan R. Liss, 1989:435-46.
10. Krege S, Giani G, Meyer R, et al. A randomized multicenter trial of adjuvant therapy in superficial bladder cancer: transurethral resection only versus transurethral resection plus mitomycin C versus transurethral resection plus bacillus Calmette-Guerin. J Urol 1996;156:962-6.
11. Lundholm C, Norlen BJ, Ekman P, et al. A randomized prospective study comparing long-term intravesical instillations of mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma. J Urol 1996;156:372-6.
12. Lamm DL, Crissman J, Blumenstein B, et al. Adriamycin versus BCG in superficial bladder cancer. A Southwest Oncology Group Study. EORTC Genitourinary Group Monogr 1989;6:263-70.
13. Mori K, Lamm DL, Crawford ED. A trial of bacillus Calmette-Guerin versus adriamycin in superficial bladder cancer. A Southwest Oncology Group Study. Urol Int 1986;41:254-9.
14. Witjes WPJ, van der Meijden APM, Roos EPM, et al. BCG-RIVM versus BCG-TICE versus mitomycin C in superficial bladder cancer. Rationale, design and interim analysis of the trial of the Southeast Cooperative Urological Group, The Netherlands. EORTC genitourinary monograph 11: recent progress in bladder and kidney cancer. New York: Wiley-Liss, 1992:59-67.
15. Witjes JA, Meijden APM, Witjes WPJ, et al. A randomized prospective study comparing intravesical instillations of mitomycin C, BCG-TICE and BCG_RIVM in pTa-pT1 tumors and primary carcinoma in situ of the urinary bladder. Eur J Cancer 1993;29A:1672-6.
16. Lamm DL, Blumenstein BA, Crawford ED, et al. A randomized trial of intravesical doxorubicin and immunotherapy with Bacille Calmette-Guerin for transitional cell carcinoma of the bladder. N Engl J Med 1991;325:1205-9.
17. Lamm DL, Blumenstein BA, Crawford ED, et al. Randomized intergroup comparison of bacillus Calmette-Guerin immunotherapy and mitomycin C chemotherapy prophylaxis in superficial transitional cell carcinoma of the bladder. A Southwest Oncology Group Study. Urol Oncol 1995;1:119-26.
18. Malmastrom P, Wijkstrom H, Lundholm C, et al. 5-year follow-up of a randomized prospective study comparing mitomycin C and bacillus Calmette Guerin in patients with superficial bladder carcinoma. J Urol 1999;161:1124-7.
19. Martinez-Pineiro JA, Leon JJ, Martinez-Pineiro L, et al. Bacillus Calmette-Guerin versus doxorubicin versus thiotepa: a randomized prospective study in 202 patients with superficial bladder cancer. J Urol 1990;143:502-6.
20. Melekos MD, Zarakovitis I, Dandinis K, et al. BCG versus epirubicin in the prophylaxis of multiple superficial bladder tumors: Results of a prospective randomized study using modified treatment schemes. Int Urol Nephrol 1996;28:499-509.
21. Melekos MD, Zarakovitis IE, Fokaefs ED, et al. Intravesical bacillus Calmette-Guerin versus epirubicin in the prophylaxis of recurrent and/or multiple superficial bladder tumors. Oncology 1996;53:281-8.
22. Rintala E, Jauhianinen K, Alfthan O, et al. Intravesical chemotherapy (mitomycin C) versus immunotherapy (bacillus Calmette-Guerin) in superficial bladder cancer. Eur Oncol 1991;20:19-25.
23. Vegt PD, Witjes JA, Witjes WPJ, et al. A randomized study of intravesical mitomycin C, bacillus Calmette-Guerin Tice and BCG-RIVM treatment of pTa-pT1 papillary carcinoma and carcinoma in situ of the bladder. J Urol 1995;153:929-33.
24. Witjes JA, Meijden APM, Collete L, et al. Long-term follow up of an EORTC randomized prospective trial comparing intravesical Bacillus Calmette-Guerin RIVM and mitomycin C in superficial bladder cancer. Urology 1998;52:403-10.
25. Huncharek M, Geschwind JF, Witherspoon B, et al. Intravesical chemotherapy prophylaxis in primary superficial bladder cancer: a meta-analysis of 3,703 patients from 11 randomized trials. J Clin Epidemiol 2000;53:676-80.
26. Huncharek M, McGarry R, Kupelnick B. Impact of intravesical chemotherapy on recurrence rate of recurrent superficial transitional cell carcinoma of the bladder: results of a meta-analysis. Anticancer Res 2001;21:765-9.
27. Messing EM, Catalona W. Urothelial tumors of the urinary tract. In: Campbell's urology. 7th ed. Walsh PC, Retik AB, Vaughn ED, et al., eds. Philadelphia: WB Saunders, 1998:2362-5.
28. Herr HW. Tumor progression and survival in patients with T1G3 bladder tumors. 15 year outcome. Br J Urol 1997;80:762-5.
29. Kilbridge KL, Kantoff P. Intravesical therapy for superficial bladder cancer: is it a wash? J Clin Oncol 1994;2:1-4.